Original Papers - Prostate Open access

Postoperative administration of a combination of Phycocyanin, PEA and Selenium following prostatic deobstructive surgery: a preliminary clinical study

Authors

Published
25 September 2026
Section
Original Papers - Prostate

Abstract

Background: Irritative urinary symptoms and postoperative pain are common after prostatic deobstructive surgery for benign prostatic hyperplasia (BPH) and may negatively affect early postoperative recovery and quality of life. Objective: To evaluate the efficacy and safety of a combination of Phycocyanin, PEA and Selenium administered during the first postoperative period in patients undergoing TransUrethral Resection of the Prostate (TURP) and Thulium transurethral VapoResection of the Prostate (ThuVaRP).

Methods: A preliminary clinical study conducted at the Urology Unit of the Istituto Clinico Città degli Studi in Milan included 197 patients undergoing prostatic deobstructive surgery for BPH. Patients received the natural complex (2 capsules/day) for 30 days after surgery. Outcomes were assessed using the International Prostate Symptom Score (IPSS), the related Quality of Life (QoL) index, the Visual Analog Scale (VAS) for pain, and clinical observations.

Results: Within 30 days after surgery, patients treated with a combination of Phycocyanin, PEA and Selenium showed a 40-60% reduction in IPSS score, with marked improvement in dysuria and urgency-related symptoms, and a 2-3 point reduction in QoL score. VAS pain scores decreased progressively over the first five postoperative days. After four weeks, the mean IPSS reduction reached 10 points. Approximately 70% of treated patients reported no clinically significant postoperative complications.

Conclusions: These preliminary findings suggest that a combination of Phycocyanin, PEA and Selenium may be effective in reducing irritative urinary symptoms, postoperative pain, and complications, while improving quality of life following prostatic deobstructive surgery.

Ethics Approval

Not applicable. Food supplements are regulated by Directive 2002/46/EC, implemented in Italy through Legislative Decree No. 169/2004, as well as by applicable national decrees and guidelines issued by the Italian Ministry of Health. The study was conducted in accordance with Good Clinical Practice guidelines and the ethical principles of the latest revision of the Declaration of Helsinki. All participants provided written informed consent before receiving any intervention.

Data Availability Statement

The datasets generated and/or analyzed during the current study are available upon reasonable request from the corresponding author.

References

  1. 1. Huang J, Chan CK, Yee S, et al. Global burden and temporal trends of lower urinary tract symptoms: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2023. DOI: https://doi.org/10.1038/s41391-022-00610-w
  2. 2. Wei JT, Dauw CA, Brodsky CN. Lower urinary tract symptoms in men: a review. JAMA 2025; 334:809-21. DOI: https://doi.org/10.1001/jama.2025.7045
  3. 3. Porto JG, Bhatia AM, Bhat A, et al. Evaluating transurethral resection of the prostate over twenty years: a systematic review and meta-analysis of randomized clinical trials. World J Urol. 2024. DOI: https://doi.org/10.1007/s00345-024-05332-3
  4. 4. Hu X, Miao J, Xie K, et al. Clinical comparison of TURP, PVP and HoLEP for small volume BPH. Sci Rep 2025. 5. Castellani D, Cormio A, Alberti A, et al. Incidence of overactive DOI: https://doi.org/10.1038/s41598-025-18395-y
  5. bladder symptoms and dysuria following transurethral interventions for benign prostatic enlargement: a systematic review and metaanalysis. Neurourol Urodyn 2025; 44:1676-88. DOI: https://doi.org/10.1002/nau.70129
  6. 6. Arora B, Khan M, Pridgeon S. Does histological prostatic inflammation during TURP affect postoperative urinary outcomes? Low Urinary Tract Symptoms 2023; 15:57-62. DOI: https://doi.org/10.1111/luts.12473
  7. 7. Saitta G, Mantovani FA, Calabrese B, et al. Prospective observational study on the efficacy and tolerability of a complex of phytochemicals versus dutasteride in the treatment of Lower Urinary Tract Symptomps due to Benign Prostatic Hyperplasia. Arch Ital Urol Androl. 2024; 96:12869. DOI: https://doi.org/10.4081/aiua.2024.12869
  8. 8. Mani V, Korrapati B, Palaniyandi V, et al. Effectiveness of transurethral resection of the prostate in managing lower urinary tract symptoms and enhancing quality of life: a prospective South Indian study. Cureus 2025; 17:e90945. DOI: https://doi.org/10.7759/cureus.90945
  9. 9. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation. J Urol 2008; 180:246-9. DOI: https://doi.org/10.1016/j.juro.2008.03.058
  10. 10. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 2006; 50:969-79. DOI: https://doi.org/10.1016/j.eururo.2005.12.042
  11. 11. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58:384-97. DOI: https://doi.org/10.1016/j.eururo.2010.06.005
  12. 12. Porru D, Madeddu G, Campus G, et al. Evaluation of morbidity of transurethral prostate resection by symptom score. Urology 2001; 57:1111-5.

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.